» Articles » PMID: 30830232

Contraceptive Methods and the Impact of Menstruation on Daily Functioning in Women with Sickle Cell Disease

Overview
Journal South Med J
Date 2019 Mar 5
PMID 30830232
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Women with sickle cell disease (SCD) are living longer as a result of advances in the care of their underlying disease. With the population growing of women living with SCD, reproductive health issues in this population have become an emphasized area of medical care. We sought to describe current patterns of contraception use, menstruation, and quality-of-life (QOL) measures in women with SCD.

Methods: Using a cross-sectional study design, we administered paper surveys at two academic medical centers to women aged 10 to 55 years with SCD to capture current contraceptive use, characteristics of menstrual cycles, and QOL metrics.

Results: Of the 103 women who participated, 12.7% (13/102) experienced a duration of menses >7 days (defined here as prolonged menstrual bleeding). Approximately half of women (51.5%, 53/103) used some form of contraception, with depot medroxyprogesterone acetate injections and condoms being the most common. During their last menstrual periods, women with both dysmenorrhea and prolonged menstrual bleeding (6.9%, 7/102) were more likely to experience more days of poor QOL, with more nights with sleep disturbance ( = 0.001) and more days with trouble taking care of themselves ( = 0.003), as well as being unable to do things they previously enjoyed ( = 0.001), compared with those with neither phenomenon (28.2%, 29/103).

Conclusions: Dysmenorrhea and prolonged menstrual bleeding negatively affect the QOL of women with SCD. Menstrual histories and preventive measures for menstruation-related morbidity should be incorporated into routine evaluations of women with SCD.

Citing Articles

Pain Frequency and Health Care Utilization Patterns in Women with Sickle Cell Disease Experiencing Menstruation-Associated Pain Crises.

Segbefia C, Campbell J, Tartaglione I, Asare E, Andemariam B, Zempsky W J Womens Health (Larchmt). 2023; 32(12):1284-1291.

PMID: 38011013 PMC: 10712351. DOI: 10.1089/jwh.2023.0023.


Comparison of thromboembolism outcomes in patients with sickle cell disease prescribed hormonal contraception.

Bala N, Stanek J, Vesely S, Cronin R, Creary S, Roe A Blood Adv. 2023; 7(20):6140-6150.

PMID: 37585480 PMC: 10582388. DOI: 10.1182/bloodadvances.2023010204.


No crystal stair: supporting fertility care and the pursuit of pregnancy in women with sickle cell disease.

Pecker L, Nero A, Christianson M Hematology Am Soc Hematol Educ Program. 2022; 2022(1):459-466.

PMID: 36485154 PMC: 9821326. DOI: 10.1182/hematology.2022000381.


Go the Distance: Reproductive Health Care for People with Sickle Cell Disease.

Pecker L, Kuo K Hematol Oncol Clin North Am. 2022; 36(6):1255-1270.

PMID: 36400542 PMC: 10242540. DOI: 10.1016/j.hoc.2022.07.010.


Pediatric hematology providers' contraceptive practices for female adolescents and young adults with sickle cell disease: A national survey.

Askew M, Smaldone A, Gold M, Smith-Whitley K, Strouse J, Jin Z Pediatr Blood Cancer. 2022; 69(10):e29877.

PMID: 35856776 PMC: 9623811. DOI: 10.1002/pbc.29877.